Pulmonx (NASDAQ:LUNG) Cut to "Sell" at Wall Street Zen

Key Points

• Pulmonx has been downgraded from a "hold" rating to a "sell" rating by Wall Street Zen, indicating a bearish outlook for the stock.
• Multiple analysts have adjusted their target prices significantly lower, with new targets ranging from $2.50 to $8.00, reflecting a decrease in confidence regarding the company's financial performance.
• The stock is currently trading at $1.84, with analysts forecasting an earnings per share of -1.55 for the current year, highlighting the company's challenging financial situation.

Pulmonx (NASDAQ:LUNG - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Friday.

A number of other analysts have also commented on the stock. Lake Street Capital lowered their target price on shares of Pulmonx from $12.00 to $8.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Pulmonx in a report on Saturday, September 27th. D. Boral Capital reaffirmed a "buy" rating and set a $16.00 target price on shares of Pulmonx in a report on Monday, September 8th. Piper Sandler lowered shares of Pulmonx from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $9.00 to $2.50 in a report on Thursday, July 31st. Finally, Stifel Nicolaus decreased their price target on shares of Pulmonx from $16.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $7.66.

Pulmonx Price Performance

Shares of Pulmonx stock traded up $0.15 during midday trading on Friday, reaching $1.84. The company had a trading volume of 577,077 shares, compared to its average volume of 325,667. The company has a current ratio of 5.35, a quick ratio of 4.63 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $74.98 million, a price-to-earnings ratio of -1.29 and a beta of 0.42. The stock has a fifty day simple moving average of $1.75 and a 200 day simple moving average of $3.27. Pulmonx has a 1-year low of $1.47 and a 1-year high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. The business had revenue of $23.86 million during the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Pulmonx will post -1.55 earnings per share for the current year.

Institutional Investors Weigh In On Pulmonx

Institutional investors have recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. bought a new stake in Pulmonx during the 1st quarter worth about $82,000. Parkman Healthcare Partners LLC lifted its position in Pulmonx by 194.4% during the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company's stock worth $4,118,000 after buying an additional 404,022 shares in the last quarter. Bank of America Corp DE lifted its position in Pulmonx by 58.8% during the 4th quarter. Bank of America Corp DE now owns 55,237 shares of the company's stock worth $375,000 after buying an additional 20,458 shares in the last quarter. Trexquant Investment LP increased its stake in shares of Pulmonx by 140.0% during the 1st quarter. Trexquant Investment LP now owns 224,909 shares of the company's stock worth $1,514,000 after purchasing an additional 131,209 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Pulmonx by 4.2% during the 1st quarter. Deutsche Bank AG now owns 1,147,105 shares of the company's stock worth $7,720,000 after purchasing an additional 46,116 shares during the last quarter. 91.04% of the stock is owned by institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.